Back

A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice

Martinez, D.; Schaefer, A.; Gobeil, S.; Li, D.; De la Cruz, G.; Parks, R.; Lu, X.; Barr, M.; Manne, K.; Mansouri, K.; Edwards, R. J.; Yount, B.; Anasti, K.; Montgomery, S.; Shen, X.; Zhou, T.; Kwong, P.; Graham, B.; Mascola, J. R.; Montefiori, D.; Alam, M.; Sempowski, G.; Wiehe, K.; Saunders, K. O.; Acharya, P.; Haynes, B.; Baric, R. S.

2021-04-28 microbiology
10.1101/2021.04.27.441655 bioRxiv
Show abstract

SARS-CoV in 2003, SARS-CoV-2 in 2019, and SARS-CoV-2 variants of concern (VOC) can cause deadly infections, underlining the importance of developing broadly effective countermeasures against Group 2B Sarbecoviruses, which could be key in the rapid prevention and mitigation of future zoonotic events. Here, we demonstrate the neutralization of SARS-CoV, bat CoVs WIV-1 and RsSHC014, and SARS-CoV-2 variants D614G, B.1.1.7, B.1.429, B1.351 by a receptor-binding domain (RBD)-specific antibody DH1047. Prophylactic and therapeutic treatment with DH1047 demonstrated protection against SARS-CoV, WIV-1, RsSHC014, and SARS-CoV-2 B1.351infection in mice. Binding and structural analysis showed high affinity binding of DH1047 to an epitope that is highly conserved among Sarbecoviruses. We conclude that DH1047 is a broadly neutralizing and protective antibody that can prevent infection and mitigate outbreaks caused by SARS-like strains and SARS-CoV-2 variants. Our results argue that the RBD conserved epitope bound by DH1047 is a rational target for pan Group 2B coronavirus vaccines.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 1%
37.4%
Similar papers in this journal
2
Cell Reports
○ 1498 papers in training set
Top 4%
7.5%
Similar papers in this journal
3
Nature
○ 645 papers in training set
Top 3%
5.9%
Similar papers in this journal
50% of probability mass above
4
Science Advances
● 1243 papers in training set
Top 5%
5.2%
Similar papers in this journal
5
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 9%
5.2%
Similar papers in this journal
6
Science
● 477 papers in training set
Top 2%
4.1%
7
eLife
● 5828 papers in training set
Top 32%
3.8%
8
Cell Host & Microbe
126 papers in training set
Top 0.8%
2.9%
9
Cell
○ 431 papers in training set
Top 4%
2.6%
10
mBio
● 833 papers in training set
Top 7%
2.3%
11
PLOS Pathogens
● 820 papers in training set
Top 5%
2.3%
12
Journal of Virology
● 499 papers in training set
Top 2%
1.6%
13
Cell Reports Medicine
○ 153 papers in training set
Top 2%
1.6%
14
Nature Microbiology
○ 155 papers in training set
Top 2%
1.6%
15
Communications Biology
○ 993 papers in training set
Top 16%
1.6%
16
Cell Research
○ 51 papers in training set
Top 0.8%
1.3%
17
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.4%
1.3%
18
Nature Medicine
○ 125 papers in training set
Top 4%
0.8%
19
iScience
○ 1154 papers in training set
Top 39%
0.8%
20
Journal of Experimental Medicine
● 119 papers in training set
Top 4%
0.6%
21
Scientific Reports
○ 3612 papers in training set
Top 79%
0.6%
22
Immunity
○ 67 papers in training set
Top 2%
0.6%
23
Cell Discovery
○ 57 papers in training set
Top 1%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.